ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМПymj-2038Research ArticleНАУЧНЫЕ ОБЗОРЫ И ЛЕКЦИИSCIENTIFIC REVIEWS AND LECTURESБиологическая терапия ювенильного ревматоидного артритаBiological treatment of juvenile rheumatoid arthritisАммосоваА. М.AmmosovaA. M.

Аммосова Аэлита Михайловна – ст. препод.

aelmma@yandex.ruАлексееваЕ. И.AlekseevaE. I.

Алексеева Екатерина Иосифовна – д.м.н., проф., зав. отделением

ХандыМ. В.HanduM. V.

Ханды Мария Васильевна – проф., зав. кафедрой

АргуноваВ. М.ArgunovaV. M.

Аргунова Вера Маична – зав. отделением

АртамоноваС. Ю.ArtamonovaS. J.

Артамонова Саргылана Юрьевна – доцент

ЗахароваН. М.ZakharovaN. M.

Захарова Надежда Михайловна – доцент

МарковаС. В.MarkovaS. V.

Маркова Сардана Валерьевна – доцент

МунхаловаЯ. А.MunhalovaJa. A.

Мунхалова Яна Афанасьевна – доцент

СтепановаЛ. А.StepanovaL. A.

Степанова Лена Анатольевна – доцент

МИ СВФУ им. М.К. АммосоваRussian FederationНаучный центр здоровья РАМН; МИ СВФУ им. М.К. АммосоваRussian FederationРБ№1-НЦМ МЗ РС(Я)Russian Federation201213102025047982Copyright © Аммосова А.М., Алексеева Е.И., Ханды М.В., Аргунова В.М., Артамонова С.Ю., Захарова Н.М., Маркова С.В., Мунхалова Я.А., Степанова Л.А., 20252025Аммосова А.М., Алексеева Е.И., Ханды М.В., Аргунова В.М., Артамонова С.Ю., Захарова Н.М., Маркова С.В., Мунхалова Я.А., Степанова Л.А.Ammosova A.M., Alekseeva E.I., Handu M.V., Argunova V.M., Artamonova S.J., Zakharova N.M., Markova S.V., Munhalova J.A., Stepanova L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/2038

В статье представлена биологическая терапия ревматоидного артрита принципиально новым классом лекарственных средств. В детской ревматологии разрешены 4 генно-инженерных биологических препарата: этанерцепт, адалимумаб, абатацепт, тоцилизумаб.

In this article the biological therapy of juvenile rheumatoid arthritis is represented by new class of drugs. Genetically engineered biological drugs are allowed to use in pediatric rheumatology: etanercept, adalimumab, abatacept, tocilizumab.

ювенильный ревматоидный артритбиологическая терапиядетиjuvenile rheumatoid arthritisbiological therapychildrenReferencesАдалимумаб – новые возможности лечения ювенильного артрита / Е.И. Алексеева, А.О. Лисицин, Н.А. Карагулян [и др.]. // Вопр. соврем. педиатр. – 2009. - № 8 (3). – С. 88–94.Adalimumab: new opportunities of rheumatoid arthritis treatment / E.I. Alekseeva, A.O. Lisitsyn, N.A. Karagulyan [et al.] / / Current Pediatrics. - 2009. - №8 (3). - P. 88-94.Алексеева Е.И. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Е.И. Алексеева, П.Ф. Литвицкий; под общей ред. акад. РА МН, проф. А.А. Баранова /.- М. - 2007. – С. 325-339.Alekseyeva E.I. Juvenile rheumatoid arthritis. Etiology. Pathogenesis. Clinic. Algorithms for diagnosis and treatment: guide for doctors, teachers, researchers / Ye.I. Alekseyeva, P.F. Litvitsky; Ed. Acad. Academy of Medical Sciences, Prof. A.A. Baranov // M., 2007. - P. 325-339.Биологическая терапия в детской ревматологии / А.А. Баранов, Е.И. Алексеева, С.И. Валиева, Т.М. Бзарова// Вестник Российской академии медицинских наук. – 2011г. - №6.Biological therapy in pediatric rheumatology / A.A. Baranov, E.I. Alekseyeva, S.I., Valiyeva, T.M. Bzarova / / Bulletin of the Russian Academy of Medical Sciences. - 2011. - № 6.Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита / Е. И. Алексеева, А.М. Алексеева, С. И.Валиева [и др.] // Вопр. соврем. педиатр. – 2008. - №7 (2) – С. 42–54.Infliximab effect on clinical and laboratory activity parameters in cases of various juvenile arthritis variants / E.I. Alekseyeva, A.M. Alekseyeva, S.I. Valiyeva [et al.] // Current Pediatrics. - 2008. - №7 (2) - P. 42-54.Место растворимых рецепторов ФНОα в лечении ювенильного идиопатического артрита / Т.М. Бзарова, Е.И. Алексеева, А.Н. Фетисова [и др.] // Вопросы современной педиатрии. – 2012. - № 11 (4). – С. 29-37.Soluble TNF receptors in the treatment of juvenile idiopathic arthritis / T.M. Bzarova, E.I. Alekseyeva, A.N. Fetisova [et al.] / / Current Pediatrics. - 2012. - №11 (4). - P. 29-37.Новые возможности терапии различных вариантов ювенильного артрита моноклональными антителами к рецептору интерлейкина 6 / Е.И. Алексеева, Р.В. Денисова, С.И. Валиева [и др.] // Вопросы современной педиатрии. –2010. - №9(1). – С.52-61.New advantages of various juvenile arthritis therapy with monoclonal antibodies to receptor interleukin 6 / E.I. Alekseyeva, Denisova R.V.,Valiyeva S.I. [et al.] // Current Pediatrics. - 2010. - №9 (1). - P.52-61.Эффективность инфликсимаба у больных ювенильным анкилозирующим спондилоартритом // Е.И. Алексеева, А.Л. Козлова, С.И. Валиева [и др.]. // Вопр. соврем. педиатр. – 2009. - №8 (2). - С. 20–26.Effectiveness of infliximab in patients with juvenile ankylosing spondylarthritis / E.I. Alekseyeva, A.L. Kozlova, S.I. Valiyeva [et al.] // Current Pediatrics. - 2009. - №8 (2). - P. 20-26.Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита / Е.И. Алексеева, С.И. Валиева, Т.М. Бзарова [и др.] // Вопр. соврем. педиатр. – 2009. - №8 (5). – Р. 51–57.Effectiveness and safety of repeated courses of treatment with rituximab in patients with severe refractory idiopathic arthritis / E.I. Alekseeva, S.I. Valiyeva, T.M. Bzarova [et al.] / / Current Pediatrics. - 2009. - №8 (5). - P. 19-30.A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) http://clinicaltrials.gov/ct2/show/.A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) http://clinicaltrials.gov/ct2/show/.Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition / M.C. Genovese, J.C. Becker, M. Schiff [et al.] // N. Engl. J. Med. – 2005. – 353. – Р. 1114–1123.Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition / M.C. Genovese, J.C. Becker, M. Schiff [et al.] // N. Engl. J. Med. – 2005. – 353. – Р. 1114–1123.Abatacept in children with juvenile idiopathic arthritis: a double-blind, placebocontrolled withdrawal trial / N. Ruperto, D.J. Lovell, P. Quartier [et al.] // The Lancet. – 2008. – № 372. - Р. 383-391.Abatacept in children with juvenile idiopathic arthritis: a double-blind, placebocontrolled withdrawal trial / N. Ruperto, D.J. Lovell, P. Quartier [et al.] // The Lancet. – 2008. – № 372. - Р. 383-391.Adalimumab in the therapy of uveitis in childhood / S. Biester, C. Deuter, H. Michels [et al.] // Br. J. Ophthalmol. – 2007. – № 91. – Р.319–324.Adalimumab in the therapy of uveitis in childhood / S. Biester, C. Deuter, H. Michels [et al.] // Br. J. Ophthalmol. – 2007. – № 91. – Р.319–324.Adalimumab in juvenile idiopathic arthritisassociated chronic anterior uveitis / P. Tynjälä, K. Kotaniemi, P. Lindahl [et al.]: // Rheumatology (Oxford). - 2008. – № 47. – Р. 339–344.Adalimumab in juvenile idiopathic arthritisassociated chronic anterior uveitis / P. Tynjälä, K. Kotaniemi, P. Lindahl [et al.]: // Rheumatology (Oxford). - 2008. – № 47. – Р. 339–344.Anakinra in the treatment of polyarticularcourse juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study / N. Ilowite, O. Porras, A. Reiff et al.// Clin. Rheumatol. – 2009. - № 28(2). - Р. 129–137.Anakinra in the treatment of polyarticularcourse juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study / N. Ilowite, O. Porras, A. Reiff et al.// Clin. Rheumatol. – 2009. - № 28(2). - Р. 129–137.Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series / P.A. Nigrovic, M. Mannion, F.H. Prince, A. Zeft [et al.] // Arthritis Rheum. – 2011. - №63 (2). – Р. 545- 55. doi: 10.1002/art.30128.Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series / P.A. Nigrovic, M. Mannion, F.H. Prince, A. Zeft [et al.] // Arthritis Rheum. – 2011. - №63 (2). – Р. 545- 55. doi: 10.1002/art.30128.Disease remission is achieved within two years in over half of methotrexate naïve patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE Trial [abstract] / R. Westhovens, M. Robles, S. Nayiager [et al.] // Arthritis Rheum. - 2009. - № 60(Suppl. 10). – Р. 638.Disease remission is achieved within two years in over half of methotrexate naïve patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE Trial [abstract] / R. Westhovens, M. Robles, S. Nayiager [et al.] // Arthritis Rheum. - 2009. - № 60(Suppl. 10). – Р. 638.Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study / F.H. Prince, M. Twilt, N.C. Jansen-Wijngaarden, L.W. van Suijlekom-Smit. // Ann. Rheum. Dis. – 2007. - № 66(5) – Р. 704–705.Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study / F.H. Prince, M. Twilt, N.C. Jansen-Wijngaarden, L.W. van Suijlekom-Smit. // Ann. Rheum. Dis. – 2007. - № 66(5) – Р. 704–705.El-Gabalawy H.D. Why do we not have a cure for rheumatoid arthritis? / H.D. El-Gabalawy, P.E. Lipsky // Arthritis Reum. – 2002. – № 4 (Suppl. 3). – P. 297-301.El-Gabalawy H.D. Why do we not have a cure for rheumatoid arthritis? / H.D. El-Gabalawy, P.E. Lipsky // Arthritis Reum. – 2002. – № 4 (Suppl. 3). – P. 297-301.Feito J.G. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF-alpha antagonists / J.G. Feito, C.A. Pereda // J. Clin. Rheumatol. – 2009. - № 15(7). – Р. 363–365.Feito J.G. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF-alpha antagonists / J.G. Feito, C.A. Pereda // J. Clin. Rheumatol. – 2009. - № 15(7). – Р. 363–365.Golimumab in patients with active rheumatoid arthritis despite treatment with Methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study / J. Kay, E.L. Matteson, B. Dasgupta [et al.] // Arthritis Rheumatism – 2008. – № 58. – Р. 964–975.Golimumab in patients with active rheumatoid arthritis despite treatment with Methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study / J. Kay, E.L. Matteson, B. Dasgupta [et al.] // Arthritis Rheumatism – 2008. – № 58. – Р. 964–975.GO-AFTER study investigators (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosisin patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial / J.S. Smolen, J. Kay, M.K. Doyle [et al.]// Lancet. – № 374 - Р. 210–221.GO-AFTER study investigators (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosisin patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial / J.S. Smolen, J. Kay, M.K. Doyle [et al.]// Lancet. – № 374 - Р. 210–221.IL-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France / T. Lequerre, P. Quartier, D. Rosellini [et al.] // Ann. Rheum. Dis. – 2008. – № 67. – Р. 302–308.IL-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France / T. Lequerre, P. Quartier, D. Rosellini [et al.] // Ann. Rheum. Dis. – 2008. – № 67. – Р. 302–308.Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials / S. Yokota, T. Imagawa, T. Miyamae, M. Mori [et al.] // Arthritis Rheum. – 2008. – № 58. - S631.Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials / S. Yokota, T. Imagawa, T. Miyamae, M. Mori [et al.] // Arthritis Rheum. – 2008. – № 58. - S631.Open label Phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement / P. Woo, N. Wilkinson, A.M. Prieur [et al.]: // Arthritis Res. Ther. – 2005. – № 7. – Р. 1281–1288.Open label Phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement / P. Woo, N. Wilkinson, A.M. Prieur [et al.]: // Arthritis Res. Ther. – 2005. – № 7. – Р. 1281–1288.Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis / D.J. Lovell, A. Reiff, N.T. Ilowite [et al.] // Arthritis Rheum. – 2008. - №58 (5). – Р. 1496-1504.Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis / D.J. Lovell, A. Reiff, N.T. Ilowite [et al.] // Arthritis Rheum. – 2008. - №58 (5). – Р. 1496-1504.Pediatric Rheumatology Collaborative Study Group Pediatric Rheumatology International Trials Organisation. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis / D.J. Lovell, N. Ruperto, S. Goodman [et al.] // N. Engl. J. Med. – 2008. – 21359 (8). - Р. 810–820.Pediatric Rheumatology Collaborative Study Group Pediatric Rheumatology International Trials Organisation. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis / D.J. Lovell, N. Ruperto, S. Goodman [et al.] // N. Engl. J. Med. – 2008. – 21359 (8). - Р. 810–820.Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) A service of the U.S. National Institutes of Health.Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) A service of the U.S. National Institutes of Health.PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease / W.J. Sandborn, B.G. Feagan, S. Stoinov [et al.] // N. Engl. J. Med. – 2007. - 19357(3), Р. 228–238.PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease / W.J. Sandborn, B.G. Feagan, S. Stoinov [et al.] // N. Engl. J. Med. – 2007. - 19357(3), Р. 228–238.Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial / E.C. Keystone, A.F. Kavanaugh, J.T. Sharp [et al.] // Arthritis Rheum. – 2004. – №50 - Р. 1400–1411.Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial / E.C. Keystone, A.F. Kavanaugh, J.T. Sharp [et al.] // Arthritis Rheum. – 2004. – №50 - Р. 1400–1411.Rituximab therapy for refractory systemiconset juvenile idiopathic arthritis / J. Narváez, C. Díaz-Torné, X. Juanola [et al.]: // Ann. Rheum. Dis. – 2009. - № 68(4). – Р. 607–608.Rituximab therapy for refractory systemiconset juvenile idiopathic arthritis / J. Narváez, C. Díaz-Torné, X. Juanola [et al.]: // Ann. Rheum. Dis. – 2009. - № 68(4). – Р. 607–608.Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade / J.S. Smolen, C. Han, D.M. van der Heijde [et al.] // Ann. Rheum. Dis. – 2009. - № 68 (6). – Р.823-827.Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade / J.S. Smolen, C. Han, D.M. van der Heijde [et al.] // Ann. Rheum. Dis. – 2009. - № 68 (6). – Р.823-827.Retrospective clinical study on the nobable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) / T. Takeuchi, H. Yamanaka, E. Inoue [et al.] // Mod. Rheumatol. – 2008. - № 18 (5) - Р. 447–454.Retrospective clinical study on the nobable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) / T. Takeuchi, H. Yamanaka, E. Inoue [et al.] // Mod. Rheumatol. – 2008. - № 18 (5) - Р. 447–454.Rituximab: A promising alternative in the treatment of systemic onset rheumatoid idiopathic arthritis (soJIA) when anti-TNF fails / CAP Testa, J.G. Feito, C.M. Arquillo // Ann. Rheum. Dis. – 2007. - № 66(Suppl. 2). - AbsSAT0415.Rituximab: A promising alternative in the treatment of systemic onset rheumatoid idiopathic arthritis (soJIA) when anti-TNF fails / CAP Testa, J.G. Feito, C.M. Arquillo // Ann. Rheum. Dis. – 2007. - № 66(Suppl. 2). - AbsSAT0415.Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report / M. KasherMeron, Y. Uziel, H. Amital // Rheumatology (Oxford). – 2009. - № 48(4). – Р. 445–446.Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report / M. KasherMeron, Y. Uziel, H. Amital // Rheumatology (Oxford). – 2009. - № 48(4). – Р. 445–446.Textbook of paediatric rheumatology, 2nd end. / Cassidy J., Petty R., eds. // New York: Churchill Livigstone – 1989.Textbook of paediatric rheumatology, 2nd end. / Cassidy J., Petty R., eds. // New York: Churchill Livigstone – 1989.

The authors declare that there are no conflicts of interest present.